China’s first AI-powered cancer vaccine production line set to launch in Beijing

China has broken ground on what developers say is the country’s first production line for AI-assisted personalised tumour vaccines, raising hopes for millions of new Cancer patients every year – a disease that ranks as the nation’s second-leading cause of death.By October, Beijing-based Likang Life Sciences is expected to complete a new drug research and manufacturing centre in the Beijing-economic-and-technological-development-zone" class="entity-link entity-location" data-entity-id="154515" data-entity-type="location">Beijing Economic and Technological Development Zone, with a total investment of about 110 million yuan (US$16.1 million), according to the district government.The facility will house cell therapy research laboratories together with a production line of the company’s flagship product, LK101, a personalised Cancer vaccine that analyses each patient’s tumour DNA to pinpoint the specific genetic mutations driving the disease. With AI, the company said the procedure could be completed in a day.